Meta-Flux is an AI-assisted diagnostics platform that utilizes multi-omic data and deep neural networks to identify clinically relevant biomarkers for various diseases. The platform enables rapid hypothesis testing and provides insights into biological interactions, facilitating more effective drug development and disease prevention strategies.
Funding
$260K raised to dateRaised to date based on public sources. This may differ from the amount the company actually raised and is based only on what is publicly available on the internet.
Founders
Product
Problem
Drug development and disease prevention are hindered by the complexity of biological interactions and the difficulty of identifying clinically relevant biomarkers from vast amounts of multi-omic data. Traditional methods struggle to efficiently test hypotheses and gain insights into the underlying mechanisms of disease.
Solution
Meta-Flux offers an AI-assisted diagnostics platform that leverages multi-omic data and deep neural networks to accelerate biomarker discovery and improve understanding of disease biology. The platform enables users to query multiple hypotheses in minutes, providing comprehensive disease network graphs that simplify complex data. By tracking multiple biological states and conditions, modeling biological interactions, and accounting for population variability, Meta-Flux helps researchers understand the impact of drugs on disease. The platform delivers comparative feedback and guided understanding across drug and disease models, facilitating more effective drug development and disease prevention strategies.
Target Audience
The primary users are researchers and drug developers in the pharmaceutical and biotechnology industries, as well as clinical researchers focused on disease prevention and diagnostics.
Features
- Expansive disease datasets incorporating multi-omic data.
- Biological state tracking across multiple conditions.
- Network modeling of biological interactions using deep neural networks.
- Analysis of drug impacts on disease mechanisms.
- Population variability analysis to reduce noise and improve accuracy.
- Comparative reporting and guided understanding across drug and disease models.
- Identification of clinically relevant biomarkers.